JP Morgan Chase’s Axsome Therapeutics AXSM Stock Holding History

JP Morgan Chase’s Portfolio AXSM Stock Details AXSM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-17,500	Closed	-$3.2M	–	7523
2025 Q4	$3.2M	Buy	+17,500	New	+$2.44M	﹤0.01%	3709
2025 Q1	–	Sell	-67,700	Closed	-$5.73M	–	7323
2024 Q4	$5.73M	Buy	+67,700	New	+$6.23M	﹤0.01%	3221
2022 Q4	–	Sell	-2,200	Closed	-$98K	–	6536
2022 Q3	$98K	Buy	+2,200	New	+$110K	﹤0.01%	5295
2020 Q2	–	Sell	-50,000	Closed	-$2.94M	–	5362
2020 Q1	$2.94M	Buy	+50,000	New	+$4.07M	﹤0.01%	2677
2019 Q3	–	Sell	-375,000	Closed	-$9.52M	–	5710
2019 Q2	$9.52M	Sell	375,000 -125,000	-25%	-$2.51M	﹤0.01%	2139
2019 Q1	$7.12M	Buy	+500,000	New	+$4.64M	﹤0.01%	2320

Other funds holding AXSM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

JP Morgan Chase's AXSM Position: Q2 2026 in Review

JP Morgan Chase reduced its Axsome Therapeutics (AXSM) stake by 40% in Q2 2026, selling an estimated $23.4M and leaving 162,065 shares worth $39.5M. The position accounts for ﹤0.01% of the portfolio, ranked #1650.

JP Morgan Chase first reported a position in AXSM in Q4 2015 and has held it in 41 quarters since. The position peaked at $43.4M in Q1 2026. 505 funds tracked by Wall St. Rank hold AXSM as of Q2 2026.

JP Morgan Chase held 162,065 shares of Axsome Therapeutics worth $39.5M as of Q2 2026.
JP Morgan Chase sold 108,095 Axsome Therapeutics shares in Q2 2026, an estimated $23.4M.
Axsome Therapeutics made up ﹤0.01% of JP Morgan Chase's portfolio in Q2 2026, its #1650 holding.
JP Morgan Chase first reported a position in Axsome Therapeutics in Q4 2015 and has held it in 41 quarters since.
JP Morgan Chase's Axsome Therapeutics position peaked at $43.4M in Q1 2026.
505 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q2 2026.

Based on JP Morgan Chase's 13F filing for Q2 2026, filed 12 Aug 2026.